StockMarketWire.com - AstraZeneca said its drug to improve glucose levels in adults with type-2 diabetes had been approved by the European Commission.

The approval was based on data from five phase III trials evaluating combinations of Forxiga (dapagliflozin) and Onglyza (saxagliptin) on a background of metformin in patients with inadequately controlled type-2 diabetes.

Across the trials, the combination of Forxiga, Onglyza and metformin was superior at reducing average blood glucose levels compared to Forxiga with metformin, Onglyza with metformin, or glimepiride with metformin, the company said.




Story provided by StockMarketWire.com